Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CASI Pharmaceuticals (CASI) Non-Current Assets (2021 - 2025)

Historic Non-Current Assets for Pharmaceuticals (CASI) over the last 5 years, with Q2 2025 value amounting to $13.0 million.

  • Pharmaceuticals' Non-Current Assets rose 10003.51% to $13.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$64.3 billion, marking a year-over-year increase of 5914.18%. This contributed to the annual value of $14.1 million for FY2024, which is 10002.38% up from last year.
  • Latest data reveals that Pharmaceuticals reported Non-Current Assets of $13.0 million as of Q2 2025, which was up 10003.51% from -$27.2 billion recorded in Q1 2025.
  • Over the past 5 years, Pharmaceuticals' Non-Current Assets peaked at $76.3 million during Q4 2021, and registered a low of -$61.0 billion during Q2 2023.
  • In the last 5 years, Pharmaceuticals' Non-Current Assets had a median value of $13.0 million in 2025 and averaged -$20.5 billion.
  • Per our database at Business Quant, Pharmaceuticals' Non-Current Assets crashed by 25992522.47% in 2023 and then soared by 10003.51% in 2025.
  • Pharmaceuticals' Non-Current Assets (Quarter) stood at $76.3 million in 2021, then crashed by 70.11% to $22.8 million in 2022, then tumbled by 259925.22% to -$59.3 billion in 2023, then skyrocketed by 100.02% to $14.1 million in 2024, then fell by 7.5% to $13.0 million in 2025.
  • Its last three reported values are $13.0 million in Q2 2025, -$27.2 billion for Q1 2025, and $14.1 million during Q4 2024.